About: orphan medicinal products

Health 01-07-2021

Incentives alone are not enough to cope with rare disease, report says

A new report by a multidisciplinary group of experts bringing together researchers, academia and the pharma industry, has urged policymakers to look beyond the EU's Orphan Medicinal Products (OMP) regulation to better address the unmet needs of patients with rare diseases.
Health 12-11-2020

Economist: ‘Premature’ to decide changes in Orphan Drugs law

Europe needs to give EU Orphan Drugs regulation more time to show its effectiveness before reviewing the incentives it provides and putting pharma innovation to the test, economist Adam Hutchings told EURACTIV in an interview.
Health 03-11-2020

Report: Without orphan drugs law, 2mn patients deprived access to therapies

In the absence of the EU orphan drugs regulation, which focuses on rare diseases, approximately two million patients would not get access to therapies, a new industry-funded report has found.
Special ReportOpinionPromoted content
Health 24-07-2020

Europe at the crossroad of Rare Diseases innovation: lessons from the past and future outlooks

In shaping the future of rare diseases policies all stakeholders should cooperate to create an environment that actively supports research and clinical development of orphan medicinal products (OMPs). This entails building synergies all across the innovation ecosystem to address the...
Health 23-07-2020

Early stakeholder dialogues crucial for success of rare orphan medicines

Early dialogue between stakeholders is crucial for the effective development and success of rare orphan drugs, used to treat patients with rare diseases, Anna Bucsics, project adviser at the mechanism of coordinated access to orphan medicinal products (MoCA), told EURACTIV in an interview.